The competition between Eli Lilly and Novo Nordisk has become one of the most closely watched battles in the global pharmaceutical industry as demand for GLP-1 medicines continues to reshape the obesity and diabetes markets. Both companies have major commercial franchises, but their recent financial trends and product strategies show different sources of opportunity and risk for investors.

Eli Lilly Has Built Strong Momentum Around Mounjaro and Zepbound

Eli Lilly has entered 2026 with substantial commercial momentum. The company reported first-quarter revenue of $19.8 billion, representing a 56% increase from the same period a year earlier. Mounjaro revenue rose 125% to $8.7 billion, while US Zepbound revenue increased 79% to $4.1 billion.

The strength of these medicines has helped Lilly raise its full-year 2026 revenue guidance to $80 billion-$83 billion. However, the company is also experiencing lower realized prices in some markets, demonstrating that strong volume growth does not eliminate pricing pressure as access to obesity treatments expands.

Novo Nordisk Faces Slower Growth but Is Expanding Wegovy

Novo Nordisk remains a major force in the GLP-1 market, but its financial trajectory has become more complicated. In the first quarter, reported sales increased 32% at constant exchange rates, helped by a $4.2 billion provision reversal. Excluding that one-time effect, adjusted sales declined 4% at constant exchange rates.

The company is attempting to counter that pressure through new versions of Wegovy. The Wegovy pill launched in the US in January 2026, while Wegovy HD, a higher-dose injectable formulation, launched in April. Novo Nordisk said the oral product had generated more than 2 million prescriptions since launch by late April, while the higher-dose formulation demonstrated 20.7% average weight loss in the STEP UP trial.

Market Leadership Will Depend on More Than GLP-1 Demand

The comparison between the two companies increasingly extends beyond current sales. Lilly has a strong pipeline that includes orforglipron, its oral GLP-1 candidate, while Novo Nordisk is investing in next-generation obesity medicines and expanding the Wegovy franchise. Both companies are also increasing manufacturing capacity to meet global demand.

Pricing and competition could nevertheless become increasingly important. As the obesity-drug market expands, governments, insurers and consumers are likely to place greater emphasis on affordability and access. For Israeli investors following global healthcare markets, the rivalry also illustrates how pharmaceutical companies can face different earnings outcomes even when they participate in the same structural growth trend.

Going forward, investors will be watching Lilly’s second-quarter results, scheduled for August 5, alongside Novo Nordisk’s first-half results on the same date. Sales growth, realized prices, prescription volumes, manufacturing expansion, regulatory progress and pipeline developments will be central to determining which company can convert the global obesity boom into more durable long-term earnings growth.